Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 10, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-17
DOI
10.1038/s41419-019-1711-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice
- (2019) Muhua Chen et al. BIOMEDICINE & PHARMACOTHERAPY
- Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
- (2018) Pratiksha Gulati et al. CLINICAL CANCER RESEARCH
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- Driving cars to the clinic for solid tumors
- (2018) Mauro Castellarin et al. GENE THERAPY
- Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
- (2018) Yanyu Pang et al. Molecular Cancer
- PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
- (2018) David C. Bishop et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
- (2018) Ning Li et al. Translational Oncology
- The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
- (2018) Huan Liu et al. Protein & Cell
- Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
- (2018) Yixin Zou et al. Journal of Hematology & Oncology
- Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
- (2017) Hua Jiang et al. Protein & Cell
- Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
- (2017) Zhenguang Wang et al. Protein & Cell
- Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor
- (2017) Vasyl Eisenberg et al. Frontiers in Immunology
- MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer
- (2017) Audrey Bouillez et al. OncoImmunology
- Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
- (2017) Inna Serganova et al. Molecular Therapy-Oncolytics
- Generation of non-viral, transgene-free hepatocyte like cells with piggyBac transposon
- (2017) Hokahiro Katayama et al. Scientific Reports
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
- (2016) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
- (2016) Yozo Nakazawa et al. Journal of Hematology & Oncology
- Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma
- (2016) Giedre Krenciute et al. MOLECULAR THERAPY
- Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM
- (2015) Zhenling Deng et al. BMC IMMUNOLOGY
- Low-cost generation of Good Manufacturing Practice–grade CD19-specific chimeric antigen receptor–expressing T cells using piggyBac gene transfer and patient-derived materials
- (2015) Saumya Ramanayake et al. CYTOTHERAPY
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
- (2015) Yi-Fan Zhang et al. Scientific Reports
- Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome–positive acute lymphoblastic leukemia
- (2014) Shoji Saito et al. CYTOTHERAPY
- Non-viral vectors for gene-based therapy
- (2014) Hao Yin et al. NATURE REVIEWS GENETICS
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
- (2012) Jinghe Huang et al. NATURE
- In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
- (2011) D.-G. Song et al. CANCER RESEARCH
- PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor
- (2011) Yozo Nakazawa et al. MOLECULAR THERAPY
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
- (2011) Evripidis Lanitis et al. MOLECULAR THERAPY
- Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
- (2010) R. Hassan et al. CLINICAL CANCER RESEARCH
- Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway
- (2009) Ming-Cheng Chang et al. BIOCHEMICAL JOURNAL
- Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
- (2009) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Binding Domain on Mesothelin for CA125/MUC16
- (2008) Osamu Kaneko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mesothelin targeted cancer immunotherapy
- (2007) Raffit Hassan et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now